Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
109.97
+0.97 (0.89%)
Mar 31, 2025, 4:00 PM EST
Novartis AG Revenue
In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth. Novartis AG had revenue of $13.56B in the quarter ending December 31, 2024, with 15.13% growth.
Revenue
51.72B
Revenue Growth
+10.85%
P/S Ratio
n/a
Revenue / Employee
681.60K
Employees
75,883
Market Cap
211.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 16.04M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| American Oncology Network | 1.76B |
| Longduoduo Company | 6.01M |
Novartis AG News
- 2 days ago - Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis - GlobeNewsWire
- 4 days ago - FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool - Benzinga
- 4 days ago - FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer - GlobeNewsWire
- 8 days ago - Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis - GlobeNewsWire
- 11 days ago - FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Benzinga
- 12 days ago - Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G - Seeking Alpha
- 12 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) - PRNewsWire
- 12 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) - GlobeNewsWire